[Prediction of effectiveness of EGFR tyrosine kinase inhibitors for the patients with by EGFR mutations].
EGFR-TKI has been synthesized as a potential target for cancer therapy because EGFR is overexpressed and associated with poor prognosis of lung cancer. It was reported that EGFR mutations were more sensitive to EGFRTKI than those without the mutations among lung cancer patients. A subgroup of patients of Asian origin, female sex, adenocarcinoma, and no history of smoking were significantly associated with a high rate of EGFR mutations. These patients with EGFR mutations were not only favorable responders but also had a longer survival than without. In this article, we discuss the EGFR-TKI predictive factors by EGFR mutations.
Uramoto
Hidetaka
H
Second Dept. of Surgery of Environmental Health School of Medicine, University of Occupational and Environmental Health.
Sugio
Kenji
K
Yasumoto
Kosei
K
D000230:Adenocarcinoma / Q000235:genetics / Q000378:metabolism; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016190:Carboplatin / Q000008:administration & dosage; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D066246:ErbB Receptors / Q000096:biosynthesis / Q000235:genetics* / Q000502:physiology; D005260:Female; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D008297:Male; D017239:Paclitaxel / Q000008:administration & dosage; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011799:Quinazolines / Q000008:administration & dosage; D015398:Signal Transduction; D012907:Smoking
D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D016190:Carboplatin; D066246:ErbB Receptors; D011505:Protein-Tyrosine Kinases; D017239:Paclitaxel; D000077156:Gefitinib